Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]

BioVision Inc, Announces The Launch Of A Multidrug Resistance Assay Kit

January 2016  |  Press Releases

BioVision Inc, Announces The Launch Of A Multidrug Resistance Assay Kit


MILPITAS, Calif. - May 6, 2016 - PRLog -- BioVision, Inc., proudly announces the launch of a Multidrug Resistance Assay Kit. The assay can be HTP adaptable and does not require special equipment. The cell-based assay shows high signal-to-noise ratio, and results can be obtained within 30 minutes. The assay uses a lipophilic non-fluorescent P-gp substrate that readily diffuses through the plasma membrane, where it is hydrolyzed to an active fluorophore by cytosolic esterases. The resulting hydrophilic fluorophore is neither membrane permeable nor a substrate for P-gp, hence it remains trapped inside the cell. In MDR1-expressing cell lines, the lipophilic pro-fluorophore is continuously extruded from the cytosol by P-gp, leading to a low intracellular fluorescence. Inhibition of P-gp-mediated efflux by a test compound leads to increased intracellular fluorescence. Specific transporter activity is quantified by comparison with fluorescence accumulated in the presence and absence of a saturating concentration of the included selective P-gp inhibitor.

Key Features:

1. Easy to use, sensitive and quantitative

2. High-Throughput compatible

3. Kit includes Verapamil, a known Pg-p inhibitor

Image Description: Dose-response curves for MDR1 inhibition by verapamil and cyclosporin A. Percent activity was calculated for each concentration by comparison to transporter activity in the presence of 100 μM verapamil (positive inhibition control) and vehicle (negative inhibition control). The Fluorescence microscopy showing increased intracellular fluorescence in the presence of verapamil (middle right panel) and cyclosporin A (lower right panel). Cells were cultured overnight on a clear-bottom 96-well plate and exposed to MDR1 substrate for 30 min following 30 min pre-incubation with either vehicle (1% DMSO), verapamil (100 μM) or cyclosporin A (10 μM). Brightfield and fluorescence images were obtained with a Nikon TE2000 inverted microscope using a 10X Plan Fluor objective. All assays were performed according to the kit protocol using MES-SA/MX2 cells (ATCC CRL-2274)

P-glycoprotein (P-gp, Multidrug Resistance Protein 1 (MDR1), EC is a member of the ATP-binding cassette (ABC) ATPase superfamily of transmembrane transporter proteins. P-gp has extremely broad substrate specificity and is capable of transporting a vast array of neutral and anionic lipophilic molecules. P-gp strongly affects the oral absorption, tissue distribution and excretion of many drugs and prevents certain lipophilic drugs from penetrating the blood brain barrier. Overexpression of P-gp confers tumor cells with resistance to chemically and pharmacologically distinct chemotherapeutic drugs (such as doxorubicin, vincristine and paclitaxel) by actively pumping them out of cells. Induction of P-gp expression is a frequent cause of treatment failure and tumor-targeted delivery of Pgp inhibitors is being investigated as a strategy for overcoming chemotherapy resistance.

Visit here for more information:

About BioVision:

BioVision, Inc. is a privately held Life Science company headquartered in the beautiful San Francisco Bay area. BioVision develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other innovative research tools for studying Apoptosis, Metabolism, Cell Proliferation, Cellular Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Stem Cell Biology, Gene Regulation, Signal Transduction, and more.

« Back